Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Fulgent Genetics's retained earnings for the quarter that ended in Mar. 2026 was $505.1 Mil.
Fulgent Genetics's quarterly retained earnings
declined
from Sep. 2025 ($553.4 Mil) to Dec. 2025 ($530.0 Mil) and
declined
from Dec. 2025 ($530.0 Mil) to Mar. 2026 ($505.1 Mil).
Fulgent Genetics's annual retained earnings
declined
from Dec. 2023 ($633.2 Mil) to Dec. 2024 ($590.5 Mil) and
declined
from Dec. 2024 ($590.5 Mil) to Dec. 2025 ($530.0 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Fulgent Genetics Retained Earnings Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Fulgent Genetics (FLGT) has a Retained Earnings of $505.1 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Retained Earnings too high?
Fulgent Genetics' current Retained Earnings is $505.1 Mil. Overall, Fulgent Genetics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Retained Earnings compare to MYGN and CSTL?
Fulgent Genetics' Retained Earnings of $505.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Diagnostics & Research company?
A good Retained Earnings depends on the Medical Diagnostics & Research industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Retained Earnings is $505.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.24, compared to a current price of $19.57 — trading 19.3% below its estimated fair value. The current Retained Earnings is $505.1 Mil. Fulgent Genetics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Retained Earnings is $505.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $19.57 is trading 19.3% below its estimated GF Value™ of $24.24.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Retained Earnings: $505.1 Mil
GF Value™: $24.24 vs. price of $19.57 (19.3% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
63GF Score
Get the complete analysis for FLGT
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
